Under the agreement, Beactica will use its drug discovery platform, Sprint, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.
Beactica CEO Per Kallblad said that they have selected Beactica’s platform to identify high-quality medicinal chemistry starting points for a number of their prioritised programs.
Financial terms of the agreement were not disclosed.